Aralez Pharma (ARLZ) Tops Q3 EPS by 3c

Aralez Pharma (NASDAQ: ARLZ) reported Q3 EPS of ($0.37), $0.03 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $24.3 million versus the consensus estimate of $22.55 million.

GUIDANCE:

Aralez Pharma sees FY2017 revenue of $95-105 million, raised from prior range of $80-100 million.

Aralez Pharma sees FY2018 revenue of $140-160 million

For earnings history and earnings-related data on Aralez Pharma (ARLZ) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Pan American Silver (PAAS) Misses Q2 EPS by 19c
• Mannatech (MTEX) Tops Q2 EPS by 53c